Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that can cause severe disability and even mortality with joint swelling, sensitivity, loss of motion and synovial tissue damage. JIA is one of the most common inflammatory joint disease.
Chronicity in autoimmune diseases depends on the balance between pro-inflammatory and anti-inflammatory responses. One of the main factors in achieving this equilibrium is T-cell co-inhibitor receptors, which are highly expressed by exhausted-T-cells.
Previous studies revealed that T cells play an important and central role in the pathogenesis of especially the oligoarticular and polyarticular forms of the disease. We aim to define the role of T cell co-inhibitory receptors (co-IRs) for predicting the outcome of JIA and try to find a novel therapeutic target molecule.
Project LeadE Sag
WP1 month 1-6: Patient recruitment for the pilot study
WP2 month 6-12: Orientation of laboratory environment, getting familiar with the relevant lab techniques, examination of PBMC and SFMC samples obtained from JIA patients at Aarhus University
WP3 month 13-24: Reporting the results of the pilot study & Establishing similar study setup at Hacettepe University
WP4 month 25-36: Study a larger JIA cohort and other autoimmune diseases at Hacettepe University
Patient participation is very important to define the unmet needs from the patient perspective. We have a mother of systemic JIA patient as Patient/Parent Research Partner, who had valuable input in identifying the research questions and in the design of the study.